ArticleMicrobiology spectrum2026
The
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The NG-test CARBA 5 and Xpert Carba-R IVD kits were tested against 269 clinical Enterobacterales isolates selected for their previously determined carbapenemase content from the ATLAS Global Surveillance program, primarily from 2020 to 2022. Antimicrobial susceptibility testing by broth microdilution was performed for aztreonam-avibactam, cefiderocol, and othe agents using EUCAST 2025 breakpoints for interpretation. The CARBA 5 and Carba-R IVD kits accurately identified all NDM (93), KPC (36), and OXA-48-like (43) carbapenemases. The CARBA 5 detected all IMP (42) and 45/47 VIM, and the Carba-R detected all VIM (47) and 21/42 IMP. Aztreonam-avibactam was active against carbapenemase-producing isolates (percent susceptible [carbapenemases]): 90.7% (NDM), 92.9% (NDM+OXA-48-like), 100% (IMP, VIM, and KPC), and 88.9% (OXA-48-like). Cefiderocol susceptibility was as follows: 38.7% (NDM), 50.0% (NDM+OXA-48-like), 77.5% (IMP), 82.5% (VIM), 75.9% (KPC), and 100% (OXA-48-like). The most common carbapenemases in Enterobacterales include NDM, KPC, and OXA-48-like enzymes, all of which were accurately identified by the CARBA 5 and Carba-R kits. Aztreonam-avibactam demonstrated potent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.